Overlapping Actions of L-Thyroxine (T4) and Steroids in Breast Cancer Cells: Mediation by Cell Surface Integrin αvβ3

Article Sidebar

PDF Download
Published Jan 6, 2024
DOI: https://doi.org/10.18103/mra.v11i12.4963

Downloads

Download data is not yet available.

Submit your own article

Register as an author to reserve your spot in the next issue of the Medical Research Archives.

Author Registration

Join the Society

The European Society of Medicine is more than a professional association. We are a community. Our members work in countries across the globe, yet are united by a common goal: to promote health and health equity, around the world.

Join Europe’s leading medical society and discover the many advantages of membership, including free article publication.

Membership

Main Article Content

Aleck Hercbergs
Oncology, The Cleveland Clinic, Cleveland OH USA
Hung-Yun Lin
Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan
Shaker A. Mousa
NanoPharmaceuticals LLC, Troy, NY USA
Matthew Leinung
Department of Medicine, Albany Medical College, Albany, NY USA
Paul J. Davis
NanoPharmaceuticals LLC, Troy, NY USA; Department of Medicine, Albany Medical College, Albany, NY USA

Abstract

The overlap of actions of nonpeptide small endocrine molecules—thyroid hormone and steroids—include two panels of actions. One set is initiated at the nuclear receptors for these hormones and a second set of actions for both hormones is initiated at the extracellular domain of plasma membrane integrin αvβ3. This brief review is concerned with integrin-based receptors on breast cancer cells. On such cells, thyroid hormone as L-thyroxine (T4) at physiological concentrations can stimulate proliferation of breast cancer cells via the thyroid hormone analogue receptor on αvβ3 and, in the absence of estrogen, via the nuclear estrogen receptor-α (ER α). Such observations emphasize the postmenopausal relevance of nuclear estrogen receptor. The deaminated T4 derivative, tetraiodothyroacetic acid (tetrac), blocks T4 actions at the integrin. An androgen receptor on the integrin mediates stimulation of breast cancer cell proliferation by dihydrotestosterone (DHT). T4 controls the activation state of the integrin, a factor that may determine the accessibility of the androgen receptor on αvβ3 to DHT and thus to DHT-driven cell proliferation. An estrogen receptor appears to be present on the integrin, but its functions have not been defined. It is not yet known whether tetrac alters function of the steroid receptors that are adjacent to the T4 binding site on αvβ3. The overlap of T4 and steroid functions in breast cancer cells may offer additional options for clinical management of this type of cancer.

Keywords: integrin αvβ3, L-thyroxine (T4), dihydrotestosterone (DHT), estrogen receptor-α (ER α),, breast cancer cell proliferation

Article Details

How to Cite
HERCBERGS, Aleck et al. Overlapping Actions of L-Thyroxine (T4) and Steroids in Breast Cancer Cells: Mediation by Cell Surface Integrin αvβ3. Medical Research Archives, [S.l.], v. 11, n. 12, jan. 2024. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/4963>. Date accessed: 23 nov. 2024. doi: https://doi.org/10.18103/mra.v11i12.4963.
ABNT APA BibTeX CBE EndNote - EndNote format (Macintosh & Windows) MLA ProCite - RIS format (Macintosh & Windows) RefWorks Reference Manager - RIS format (Windows only) Turabian
Issue
Vol 11 No 12 (2023): December Issue, Vol.11, Issue 12
Section
Research Articles

The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.

 

References

1. Tang HY, Lin HY, Zhang S, Davis FB, Davis PJ. Thyroid hormone causes mitogen-activated protein kinase-dependent phosphorylation of the nuclear estrogen receptor. Endocrinology. 2005 Jul; 145(7):3265-3272.
2. Cheng SY, Leonard JL, Davis PJ. Molecular aspects of thyroid hormone actions. Endocr Rev. 2010 Apr; 31(2):139-170.
3. Bergh JJ, Lin HY, Lansing L, Mohamed SN, Davis FB, Mousa S, et al. Integrin aαvβ3 contains a cell surface receptor for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. Endocrinology. 2005; 146:1864-1871.
4. Davis PJ, Mousa SA, Lin HY. Nongenomic actions of thyroid hormone: the integrin component. Physiol Rev. 2021; 101:319-352.
5. Davis PJ, Mousa SA, Cody V, Tang H-Y, Lin H-Y. Small molecule hormone or hormone-like ligands of integrin αvβ3 : implications for cancer cell behavior. Horm Cancer. 2013; 4:335-342.
6. Leith JT, Hercbergs A, Kenney S, Mousa SA, Davis PJ. Activation of tumor cell integrin αvβ3 by radiation and reversal of activation by chemically-modified tetraiodothyroacetic acid (tetrac). Endocr Res. 2018 Nov; 43(4):215-219.
7. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Res Cancer. 2010 (Jan); 10(1):9-22.
8. Tosovic A, Bondeson A-G, Bondeson L, Ericson U-B, Manjer J. T3 levels in relation to prognostic factors in breast cancer: a population-based prospective cohort study. BMC Cancer. 2014; 14:536.
9. Hall LC, Salazar EP, Kane SR, Lin N. Effects of thyroid hormones on human breast cancer cell proliferation. J Steroid Biochem Mol Biol. 2008 Mar; 109 (1-2):57-66.
10. Nogueira CR, Brentan MM. Triiodothyronine mimics the effects of estrogen in breast cancer cell lines. J Steroid Biochem Mol Biol. 1996 Nov; 59(3-4):271-279.
11. Sar P, Peter R, Rath B, Mohapatra AD, Mishra SA. 3,3’,5-Triiodo L thyronine induces apoptosis in human breast cancer MCF-7 cells, repressing SMP30 expression through negative thyroid response elements. PLoS One. 2011;6(6):e20861.
12. Hercbergs A, Johnson RE, Ashur-Fabian O, Garfield DH, Davis PJ. Medically induced euthyroid hypothyroxinemia may extend survival in compassionate need cancer patients: an observational study. Oncologist. 2015 Jan; 20(1):72-76.
13. Lin H-Y, Glinsky GV, Mousa SA, davis PJ. Thyroid hormone and anti-apoptosis in tumor cells. Oncotarget. 2015 Jun 20;6(17):14735-14743.
14. Leith JT, Moiusa SA, Hercbergs A, Lin H-Y, Davis PJ. Radioresistance of cancer cells, integrin αvβ3 and thyroid hormone. Oncotarget. 2018 Dec 11; 9(97):37069-37075.
15. Lin H-Y, Tang H-Y, Davis FB, Mousa SA, Incerpi S, Luidens MK, Meng R, davis PJ. Nongenomic regulation by thyroid hormone of plaama membrane ion and small molecule pumps. Discovery Med. 2012 Sept; 14(76):199-206.
16. Mousa SA, Glinsky GV, Lin H-Y, Ashur-Fabian O, Hercbergs A, Keating KA, Davis PJ. Contributions of thyroid hormone to cancer metastasis. Biomedicines. 2018 Aug 22;6(3):89.
17. Leith JT, Davis PJ, Mousa SA, Hercbergs AA. In vitro effects of tetraiodothyroacetic acid combined with X-irradiation on basal cell carcinoma cells. Cell Cycle. 2017; 16(4):367-373.
18. Cristofanilli M, Yamaura Y, Kau S-W, bevers T, Strom S, Patangan M, Hsu L, Krishnamurthy S, Theriault RL, Hortobagyi GN. Thyroid hormone and bresst carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma. Cancer. 2005(Mar 15);103:1122-1128.
19. Angelosi A, Diamanti-Kandarakis E, Zapanti E, Nonni A, Ktenas E, Mantzou A, Kontzoglou K, Kouraklis G. Is there an association between thyroid function abnormalities and breast cancer? Arch Endocrinol Metab. 2017 (Jan-Feb);61(1):54-61.
20. Tran T-V-T, Kitahara CM, Leenhardt L, de Vathaire F, Boutron-Ruault MC, Journy N. The effect of thyroid dysfunction on breast cancer risk: an updated meta-analysis. Endocr Relat Cancer. 2022 Dec12; 30(1):e220155.
21. Tosovic A, Becker C, Bondeson A-G, Ericsson U-B, Malm J, Manjer J. Prospectively measured thyroid hormones and thyroid peroxidase antibodies in relation to breast cancer risk. Int J Cancer. 2012 Nov 1;131(9):2126-2133.
22. Yang H, Holowko N, Grassmann F, Eriksson M, Hall P, Czene K. Hyperthyroidism is associated with breast cancer risk and mammographic and genetic risk predictors. BMC Med. 2020 Aug 25; 18(1):225.
23. Wahdan-Alaswad RS, Edgerton SM, Salem H, Kim HM, Choon A, Finlay-Schultz J, Wellberg EA, Sartorius CA, Jacobsen BM, Haugen BR, Liu B, Thor AD. Exogenous thyroid hormone is associated with shortened survival and upregulatin of high-risk gene expression profiles in steroid receptor-positive breast cancers. Clin Cancer Res. 2021 Jan 15; 27(2):585-597.
24. Hercbergs A, Mousa SA, Davis PJ. Nonthyroidal illness syndrome and thyroid hormone actions at integrin αvβ3. J Clin Endocrinol Metab. 2018 Apr 1; 103(4):1291-1295.
25. Schmohl K, Nelson PJ, Spitzweg C. Tetrac as an anti-angiogenic agent in cancer. Endocr Relat Cancer. 2019 Jun 1;26(6):R287-R304.